Insights from 2023 ASCO® Annual Meeting

 

Insights from 2023 ASCO® Annual Meeting
M

ASCO® 2023 Insights: "RUBY Trial - PROs in Primary Advanced or Recurrent Endometrial Cancer for Pts Treated With Dostarlimab + Carboplatin/Paclitaxel vs. CP"

By Insights from 2023 ASCO® Annual Meeting FEATURING Mansoor Raza Mirza
By Insights from 2023 ASCO® Annual Meeting FEATURING Mansoor Raza Mirza
178 views
June 23, 2023
0 Comments
Login to view comments. Click here to Login

Featured Video

20:59
Exelixis

Primary Analysis and Follow-up Data of a Combination Therapy in 1L a…

Feat. S. Ratnam

Featured Video

21:17
Janssen Oncology

The Man Cave

Feat. J. Hamilton, M. Fabrizio, M. Taha
GYN
08:10
Insights from 2023 ASCO® Annual Meeting

Initial Efficacy & Safety Results From a Phase 2 ENGOT-ov60/GOG-…

Feat. S. Banerjee
12:42
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "RUBY Trial - PROs in Primary Advanced or …

Feat. M. Raza Mirza
07:24
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "BRCA1 and RAD51 Methylation Impact on Out…

Feat. H. Blons
06:29
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "TEDOVA Trial - Neo-Epitope Based Vaccine …

Feat. A. Leary
09:28
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "A Phase II Basket Trial of Dual Anti-CTLA…

Feat. Y. Chae